Stephen Russell, president and CEO of Vyriad (Vyriad)

Re­gen­eron-backed on­colyt­ic virus start­up scores mod­est Se­ries B ex­ten­sion

Three years ago, Re­gen­eron col­lab­o­rat­ed with tiny, Rochester, MN biotech Vyr­i­ad to kick­start a Phase II tri­al. That col­lab­o­ra­tion deal would com­bine Re­gen­eron’s PD-1 drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.